Summary: While 18F-florzolotau tau PET is an emerging biomarker for progressive supranuclear palsy (PSP), its interpretation has been hindered by a lack of consensus on visual reading and potential biases in conventional semi-quantitative analysis. As clinical manifestations and regions of elevated 18F-florzolotau binding are highly overlapping in PSP and the Parkinsonian type of multiple system atrophy (MSA-P), developing a reliable discriminative classifier for 18F-florzolotau PET is urgently needed. Herein, we developed a normalization-free deep-learning (NFDL) model for 18F-florzolotau PET, which achieved significantly higher accuracy for both PSP and MSA-P compared to semi-quantitative classifiers. Regions driving the NFDL classifier’s...
OBJECTIVES: Progressive supranuclear palsy (PSP) is characterized by deposition of straight filament...
This investigation of [18F]FDDNP was conducted in an effort to confirm the presence of disease in a ...
Objective18 F-flortaucipir (formerly 18 F-AV1451 or 18 F-T807) binds to neurofibrillary tangles in A...
While 18F-florzolotau tau PET is an emerging biomarker for progressive supranuclear palsy (PSP), its...
While F-18-florzolotau tau PET is an emerging biomarker for progressive supranu-clear palsy (PSP), i...
Progressive supranuclear palsy (PSP) is a neurodegenerative movement disorder characterized by depos...
BACKGROUND: Accumulation of cortical and subcortical tau pathology is the primary pathological subst...
[Objective] We aim to establish a diagnostic system for progressive supranuclear palsy (PSP) by tau ...
PURPOSE: The purpose of this study was to evaluate whether the pattern of striatal dopamine transpor...
Background: Progressive supranuclear palsy (PSP) is a 4-repeat (4R) tauopathy and region-specific ta...
<p>Background: F-18-fluordeoxyglucose positron emission tomography (FDG-PET) is widely used for disc...
Background: Progressive supranuclear palsy (PSP) is difficult to diagnose accurately. The recently d...
Background: F-18-fluordeoxyglucose positron emission tomography (FDG-PET) is widely used for discrim...
Importance: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggreg...
Importance: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggreg...
OBJECTIVES: Progressive supranuclear palsy (PSP) is characterized by deposition of straight filament...
This investigation of [18F]FDDNP was conducted in an effort to confirm the presence of disease in a ...
Objective18 F-flortaucipir (formerly 18 F-AV1451 or 18 F-T807) binds to neurofibrillary tangles in A...
While 18F-florzolotau tau PET is an emerging biomarker for progressive supranuclear palsy (PSP), its...
While F-18-florzolotau tau PET is an emerging biomarker for progressive supranu-clear palsy (PSP), i...
Progressive supranuclear palsy (PSP) is a neurodegenerative movement disorder characterized by depos...
BACKGROUND: Accumulation of cortical and subcortical tau pathology is the primary pathological subst...
[Objective] We aim to establish a diagnostic system for progressive supranuclear palsy (PSP) by tau ...
PURPOSE: The purpose of this study was to evaluate whether the pattern of striatal dopamine transpor...
Background: Progressive supranuclear palsy (PSP) is a 4-repeat (4R) tauopathy and region-specific ta...
<p>Background: F-18-fluordeoxyglucose positron emission tomography (FDG-PET) is widely used for disc...
Background: Progressive supranuclear palsy (PSP) is difficult to diagnose accurately. The recently d...
Background: F-18-fluordeoxyglucose positron emission tomography (FDG-PET) is widely used for discrim...
Importance: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggreg...
Importance: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggreg...
OBJECTIVES: Progressive supranuclear palsy (PSP) is characterized by deposition of straight filament...
This investigation of [18F]FDDNP was conducted in an effort to confirm the presence of disease in a ...
Objective18 F-flortaucipir (formerly 18 F-AV1451 or 18 F-T807) binds to neurofibrillary tangles in A...